Tocilizumab for steroid refractory acute graft-versus-host disease

被引：36

作者：

Roddy, Julianna V. F. ^{[1
]}

Haverkos, Bradley M. ^{[2
]}

McBride, Ali ^{[3
]}

Leininger, Kathryn M. ^{[2
]}

Jaglowski, Samantha ^{[2
]}

Penza, Sam ^{[2
]}

Klisovic, Rebecca ^{[2
]}

Blum, William ^{[2
]}

Vasu, Sumithira ^{[2
]}

Hofmeister, Craig C. ^{[2
]}

Benson, Don M. ^{[2
]}

Andritsos, Leslie A. ^{[2
]}

Devine, Steven M. ^{[2
]}

Efebera, Yvonne A. ^{[2
]}

机构：

[1] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Dept Pharm, Columbus, OH 43210 USA

[2] Ohio State Univ, James Canc Hosp, Div Hematol, Dept Internal Med,Comprehens Canc Ctr, Columbus, OH 43210 USA

[3] Univ Arizona, Ctr Canc, Dept Pharm, Tucson, AZ USA

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 01期

关键词：

Antibody-based immunotherapy; cytokine and chemokine biology; clinical results; graft-versus-host disease; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; DOUBLE-BLIND; INTERLEUKIN-6; ARTHRITIS; RESISTANT; EFFICACY; PROTEIN; GVHD;

D O I：

10.3109/10428194.2015.1045896

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute graft-versus-host-disease (aGVHD) is a frequent and often lethal complication of allogeneic hematopoietic stem cell transplant despite prophylaxis. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody that has evidence of activity in patients with steroid refractory (SR) GVHD. We retrospectively report on nine patients with grade 3 or 4 SR aGVHD who received tocilizumab. Eight mg/kg of tocilizumab was administered intravenously every 3-4 weeks. aGVHD grading and responses were based on consensus criteria. Median age at transplant was 48 years. Five patients had alternate donor sources. Median time from aGVHD onset to tocilizumab administration was 44 days. Two patients had complete responses and two had partial responses. Median survival from start of tocilizumab was 26 days (range 13-1054). Our limited experience demonstrated an overall response rate of 44% (CR + PR); however, this response was not durable. Further studies are needed to determine the optimal time for tocilizumab initiation.

引用

页码：81 / 85

页数：5

共 21 条

[1] Innovative approaches to treat steroid-resistant or steroid refractory GVHD [J].

Berger, M. ;

Biasin, E. ;

Saglio, F. ;

Fagioli, F. .

BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 2) :S101-S105

[2] Pentostatin in steroid-refractory acute graft-versus-host disease [J].

Bolaños-Meade, J ;

Jacobsohn, DA ;

Margolis, J ;

Ogden, A ;

Wientjes, MG ;

Byrd, JC ;

Lucas, DM ;

Anders, V ;

Phelps, M ;

Grever, MR ;

Vogelsang, GB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2661-2668

[3] Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation [J].

Busca, Alessandro ;

Locatelli, Franco ;

Marmont, Filippo ;

Ceretto, Cristina ;

Falda, Michele .

AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (01) :45-52

[4] Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation [J].

Cavet, J ;

Dickinson, AM ;

Norden, J ;

Taylor, PRA ;

Jackson, GH ;

Middleton, PG .

BLOOD, 2001, 98 (05) :1594-1600

[5] Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease [J].

Chen, Xiao ;

Das, Rupali ;

Komorowski, Richard ;

Beres, Amy ;

Hessner, Martin J. ;

Mihara, Masahiko ;

Drobyski, William R. .

BLOOD, 2009, 114 (04) :891-900

[6] How I treat refractory acute GVHD [J].

Deeg, H. Joachim .

BLOOD, 2007, 109 (10) :4119-4126

[7] Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease [J].

Drobyski, William R. ;

Pasquini, Marcelo ;

Kovatovic, Kathy ;

Palmer, Jeanne ;

Rizzo, J. Douglas ;

Saad, Ayman ;

Saber, Wael ;

Hari, Parameswaran .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (12) :1862-1868

[8] Graft-versus-host disease [J].

Ferrara, James L. M. ;

Levine, John E. ;

Reddy, Pavan ;

Holler, Ernst .

LANCET, 2009, 373 (9674) :1550-1561

[9] Effectiveness and Safety of Tocilizumab, an Anti-Interleukin-6 Receptor Monoclonal Antibody, in a Patient With Refractory GI Graft-Versus-Host Disease [J].

Gergis, Usama ;

Arnason, Jon ;

Yantiss, Rhonda ;

Shore, Tsiporah ;

Wissa, Usama ;

Feldman, Eric ;

Woodworth, Thasia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :E602-E604

[10]

GIVON T, 1994, BLOOD, V83, P1690

← 1 2 3 →